Authors

• Kazuto Nishio (ORCID: https://orcid.org/0000-0002-8275-0846)
• Kazuo Kasahara (ORCID: https://orcid.org/0000-0001-5551-1543)
• S. Varughese (ORCID: https://orcid.org/0000-0002-0851-5709)
• Bente Frimodt‐Moller
• Sotaro Enatsu
• Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
• Miyako Satouchi (ORCID: https://orcid.org/0000-0003-0613-9487)
• E.B. Garon
• Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0003-3742-5419)
• Kiyotaka Yoh (ORCID: https://orcid.org/0000-0001-6928-357X)
• Martin Reck (ORCID: https://orcid.org/0000-0002-5336-9739)
• Tomoko Matsui (ORCID: https://orcid.org/0000-0003-3201-6106)
• Carla Visseren‐Grul (ORCID: https://orcid.org/0000-0003-2010-1514)
• Makoto Nishio (ORCID: https://orcid.org/0000-0003-4969-4165)
• Michelle Carlsen
• Kazuhiko Nakagawa (ORCID: https://orcid.org/0000-0003-1284-9776)
• K. Sakai (ORCID: https://orcid.org/0000-0002-9357-9394)
• Takashi Seto

Institutions

• Eli Lilly (United States) (US)
• National Hospital Organization Kyushu Cancer Center (JP)
• Eli Lilly (Japan) (JP)
• Translational Research in Oncology (FR)
• Eli Lilly (India) (IN)
• Eli Lilly (Netherlands) (NL)
• German Center for Lung Research (DE)
• The Cancer Institute Hospital (JP)
• National Cancer Center Hospital East (JP)
• Osaka International Cancer Institute (JP)
• Nippon Medical School Hospital (JP)
• Hyogo Prefectural Cancer Center (JP)
• Japanese Foundation For Cancer Research (JP)
• Kindai University (JP)

Publication Details

Journal

JTO Clinical and Research Reports

Published

2025-02-28

DOI

https://doi.org/10.1016/j.jtocrr.2025.100819

Citations

2

Primary Topic

Lung Cancer Treatments and Mutations

Type

article

Field-Weighted Citation Impact

3.04

Funders

• Eli Lilly and Company
• Eli Lilly Japan